Lead Plaintiff Deadline is May 5, 2025CLICK HERE TO PROVIDE CONTACT INFORMATION AND JOIN THE CASENEW YORK, March 25, 2025 /PRNewswire/ -- Wolf Haldenstein Adler Freeman & Herz LLP ("Wolf Haldenstein") announces that a securities class action lawsuit has been filed against Maravai LifeSciences Holdings, Inc. ("Maravai" or "the Company") (NASDAQ:MRVI) on behalf of all persons and entities that purchased or otherwise acquired Maravai securities between August 7, 2024 and February 24, 2025, both dates inclusive ...

Core Viewpoint - A class action securities lawsuit has been filed against Maravai LifeSciences Holdings, Inc. due to alleged securities fraud affecting investors between August 7, 2024, and February 24, 2025 [1][2]. Group 1: Allegations - The lawsuit claims that Maravai lacked adequate internal controls over financial reporting related to revenue recognition [2] - It is alleged that the Company inaccurately recognized revenue on certain transactions during fiscal 2024 [2] - The complaint also states that Maravai's goodwill was overstated, leading to materially misleading positive statements about the Company's business and prospects [2] Group 2: Legal Process - Investors who suffered losses during the specified timeframe have until May 5, 2025, to request to be appointed as lead plaintiff [3] - Participation in the lawsuit does not require serving as a lead plaintiff, and class members may be entitled to compensation without any out-of-pocket costs [3] Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securing compensation for shareholders and has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4]

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Q4 2024 Earnings Conference Call March 20, 2025 5:00 PM ET Company Participants Deb Hart - Head, IR Kevin Herde - EVP and CFO Trey Martin - CEO Conference Call Participants Matt Stanton - Jeffries Doug Schenkel - Wolfe Research Matt Larew - William Blair Ricki Levitus - Guggenheim Tejas Savant - Morgan Stanley Dan Arias - Stifel Catherine Schulte - Baird Matt Sykes - Goldman Sachs Brandon Coulliard - Wells Fargo Anna Snopkowski - KeyBanc Capital Markets Oper ...

Group 1 - Maravai LifeSciences Holdings, Inc. held its Q4 2024 earnings conference call on March 20, 2025, with key participants including CEO Trey Martin and CFO Kevin Herde [1][3] - The call included a formal presentation followed by a question and answer session, indicating an interactive format for discussing financial results [2][3] - The agenda for the call was outlined in the presentation slides, which were made available on the company's investor relations website [3] Group 2 - Management indicated that forward-looking statements would be made during the call, along with references to both GAAP and non-GAAP financial measures [4] - The company provided reconciliations to the most directly comparable GAAP measures in their press release and on their investor website [4]

NASDAQ: MRVI Q4 and Year-end 2024 Financial Results 01 Welcome Deb Hart, Head of Investor Relations 02 10-K Update, Financial Results & Guidance Kevin Herde, Chief Financial Officer 03 Business Highlights & Strategy Trey Martin, Chief Executive Officer 04 Q&A Session Trey Martin, Chief Executive Officer Kevin Herde, Chief Financial Officer © 2025 Maravai LifeSciences 2 Forward Looking Statements and Use of Non-GAAP Financial Measures This presentation contains, and our officers and representatives may, from ...

Maravai LifeSciences (MRVI) Q4 2024 Earnings Call March 20, 2025 05:00 PM ET Company Participants Deb Hart - Head of Investor RelationsKevin Herde - Executive VP & CFOTrey Martin - CEODoug Schenkel - Managing DirectorRicki Levitus - Equity Research Associate - Life Sciences Tools & DiagnosticsDan Arias - Managing DirectorBrandon Couillard - Managing Director Conference Call Participants Matt Stanton - AnalystMatt Larew - Research Analyst - HealthcareTejas Savant - Executive Director & Senior Healthcare Equi ...

NEW YORK, March 20, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI).Shareholders who purchased shares of MRVI during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/maravai-lifesciences-holdings-inc-loss-submission-form/?id=137092&fr ...

SAN DIEGO, March 19, 2025 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) securities between August 7, 2024 and February 24, 2025, all dates inclusive (the "Class Period"), have until May 5, 2025 to seek appointment as lead plaintiff of the Maravai class action lawsuit.  Captioned Nelson v. Maravai LifeSciences Holdings, Inc., No. 25-cv-00499 (S.D. Cal.), the Maravai class action lawsuit charges Maravai as well as ...

LOS ANGELES, March 19, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Maravai LifeSciences Holdings, Inc. ("Maravai" or "the Company") (NASDAQ: MRVI) violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between August 7, 2024 and February 24, 2025, inclusive (the "C ...

Core Viewpoint - A class action lawsuit has been filed against Maravai LifeSciences Holdings, Inc. for allegedly misrepresenting its financial condition and revenue recognition practices during a specified period [1][2]. Group 1: Allegations - The lawsuit alleges that Maravai lacked adequate internal controls over financial reporting related to revenue recognition [2] - It is claimed that the company inaccurately recognized revenue on certain transactions during fiscal 2024 [2] - The complaint also states that Maravai's goodwill was overstated, leading to materially misleading statements about the company's business and prospects [2] Group 2: Stock Impact - Following the revelation of an error in revenue recognition and a material weakness in internal controls, Maravai's stock price fell over 21% to close at $3.14 per share on February 25, 2025 [3] Group 3: Class Action Participation - Shareholders interested in serving as lead plaintiffs must file their papers with the court by May 5, 2025 [4] - Shareholders can remain absent class members if they choose not to participate in the case [4] Group 4: Company Background - Maravai LifeSciences is a life sciences company that provides products for drug therapy development, diagnostics, novel vaccines, and research support on human diseases globally [1]